OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OpGen (NASDAQ: OPGN ) just reported results for the second quarter of 2024. OpGen reported earnings per share of -$1.18.

OPGN Stock Earnings: OpGen Reported Results for Q2 2024

OpGen (NASDAQ: OPGN ) just reported results for the fourth quarter of 2023. OpGen reported earnings per share of -$17.67.

OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023

ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”).

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol “OPGN.” The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505.

OpGen Announced 1-for-10 Reverse Stock Split

ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's (“Curetis”), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings.

OpGen Provides Update on Business Operations and Strategic Opportunities

ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense.

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes.

OpGen Announces Acquisition of Preferred Stock by David Lazar

ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.

OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

OpGen (NASDAQ: OPGN ) stock is undergoing a massive rally on Thursday following a couple of pieces of news from the precision medicine company. The first bit of news worth mentioning is a progress update on a product sale.

Why Is OpGen (OPGN) Stock Up 540% Today?

OpGen (NASDAQ: OPGN ) stock is on the rise Friday after the precision medicine company withdrew a share offering. A filing with the Securities and Exchange Commission (SEC) has the company requesting the withdrawal of its Registration Statement on Form S-1.

Why Is OpGen (OPGN) Stock Up 115% Today?

OpGen, Inc. (NASDAQ:OPGN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Oliver Schacht - President and CEO Albert Weber - Chief Financial Officer Conference Call Participants Operator Welcome to OpGen's Second Quarter 2023 Earnings Call and Business Update. Before we turn the call over to OpGen management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

OpGen, Inc. (OPGN) Q2 2023 Earnings Call Transcript

ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

ROCKVILLE, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.

OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has signed an extended and continued research and development (“R&D”) collaboration agreement with FIND. Following the successful completion of the feasibility phase of the collaboration and having met all milestones on time and within budgets, the parties now plan to collaborate on first phases of product development of an antimicrobial resistance (AMR) cartridge from blood culture that is tailored to the needs of low- and middle-income countries (LMICs) in terms of panel design and coverage of specific genetic variants of bacterial strains and their AMR markers in such countries, as well as ensuring attractive cost profile and pricing models that allow for access to such rapid testing in LMICs.

OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities.

OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., July 19, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.

OpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND

Adaptimmune Therapeutics

Tradeweb Markets

Valmont Industries

Versus Systems

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).

Buy 5 Top-Ranked Stocks With Rising P/E in July

ROCKVILLE, Md., June 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.

OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe

ROCKVILLE, Md., June 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.

OpGen's Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments

AGCO

A10 Networks

Duckhorn Portfolio

Pinduoduo Inc - ADR

Do you have more faith in DuPont analysis than simple ROE calculation? Tap PDD Holdings Inc. (PDD), OpGen (OPGN), AGCO (AGCO), A10 Networks (ATEN) and The Duckhorn Portfolio (NAPA).

Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns

ROCKVILLE, Md., June 20, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its Principal Scientist Dr. Matthias Klein has presented results from the clinical trial for its Unyvero Urinary Tract Infection Panel during ASM Microbe's In Depth Symposium session ‘The Year in Clinical Microbiology' on June 17th in Houston, TX. Based on over 1,800 patient samples, the presentation titled “Multi-Center Clinical Trial Using a Novel Semi-Quantitative Multiplex-PCR Based Diagnostic Panel for Urinary Tract Specimens” summarized the objectives of the clinical trial, the Unyvero UTI panel coverage and result evaluation recommendations based on multiple reference testing methods applied during the study.

OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference

Caterpillar

ChargePoint Holdings

The RealReal

Trevena

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).

Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E

Equity Commonwealth

Horizon Technology Finance

NextNav

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), Horizon Technology Finance (HRZN), Equity Commonwealth (EQC), NOV (NOV) and Spartacus Acquisition (NN).

Go Beyond Bargain Hunting, Buy 5 Stocks With Rising P/E

OpGen Inc. (NASDAQ:OPGN ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Oliver Schacht – President and Chief Executive Officer Albert Weber – Chief Financial Officer Conference Call Participants Pooya Hemami – Edison Group Yi Chen – H.C. Wainwright Operator Welcome to the OpGen First Quarter 2023 Earnings Call and Business Update.

News for OpGen Stock (OPGN)